Parkinson's Drug Doesn't Slow Disease Progress, FDA Staff Says
WASHINGTON -- Azilect (rasagiline), which is already approved to treat symptoms of Parkinson's disease, does not appear effective at slowing progression of the neurodegenerative disease, according to an FDA review.
Oct 14, 2011